Navigation Links
WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
Date:3/5/2013

SHANGHAI and PALO ALTO, Calif., March 5, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced a second agreement to expand WuXi's use of OMT's OmniRat™ and OmniMouse™ technologies to strengthen the development and commercial opportunities for WuXi's Asian regional and global clients.

The OmniRat platform has now been duplicated at WuXi's Shanghai facility, enabling WuXi to generate antibodies for customers from its own laboratories. WuXi is the first and currently the only company authorized by OMT to host OmniRat in China. This transaction advances WuXi's goal of working with skilled partners to enhance the company's technologies and capabilities to better serve its customers.

Under the new agreement, WuXi's clients can choose to develop and commercialize products globally or regionally in China, Korea, Japan or other Asian territories. Clients that opt for regional rights first can assume global rights prior to the first human dose. This is particularly attractive for companies that have already established regional Asian operations and have aspirations to become global later. OMT retains the global product rights until and unless each option is exercised.

"This new agreement allows WuXi to further expand its service offerings with the OmniRat and OmniMouse platforms," said Edward Hu , Chief Operating Officer and Chief Financial Officer of WuXi PharmaTech. "WuXi is proud of the confidence OMT has shown in the quality of WuXi's antibody research capabilities and intellectual property protection practices in authorizing WuXi to host the OmniRat and OmniMouse platforms in our laboratories."

Dr. Roland Buelow , founder and CEO of OMT, continued, "This second agreement with WuXi continues the global deployment of OMT's human antibody technologies. The deal structure enables OMT to tap into the economics of rapidly growing Asian companies and, when global rights are not exercised by WuXi's clients, to leverage their data for OMT product development and/or partnering outside Asia."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners shorten the cycle and lower the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies – "naturally optimized human antibodies™".

OMT has created OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OMT's genetic engineering is based on an improved understanding of B cell development and a new approach to inactivation of endogenous antibody expression, which enables OmniRat to make antibodies with human idiotypes as efficiently as wild type rats make normal antibodies. OmniRat represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies, available worldwide for all targets and indications.

OMT also develops a transgenic mouse, OmniMouse™, to complement OmniRat and further increase epitope coverage in human antibody development.

OmniAb™ integrates OMT's transgenic animal platforms, proven protein and DNA immunization and Gel-Encapsulated Microenvironment (GEM) deep antibody screening to enable fast and cost-efficient generation and identification of preferred human therapeutic antibody candidates.

For more information, please visit www.wuxiapptec.com and www.omtinc.net or contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Phone: +1-201-585-2048
E-mail: Ron_Aldridge@wuxiapptec.com

Brian Lundstrom
Chief Business Officer
Open Monoclonal Technology, Inc.
Phone: + 1-775-420-7750
E-mail: bl@omtinc.net


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
2. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
3. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
4. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
5. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
6. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
7. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
8. WuXi PharmaTech Announces Second-Quarter 2012 Results
9. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
10. WuXi PharmaTech Announces First-Quarter 2012 Results
11. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):